An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Uproleselan Administered Via the Intravenous Route to Healthy Subjects (ADME Study of IV [14C]-Uproleselan in Healthy Subjects)
Phase of Trial: Phase I
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Uproleselan-sodium (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Deep vein thrombosis; Multiple myeloma; Stem cell mobilisation
- Focus Pharmacokinetics
- Sponsors GlycoMimetics
- 13 May 2019 Status changed from active, no longer recruiting to completed.
- 22 Oct 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 03 Aug 2018 New trial record